Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aurobindo Pharma gains after receiving USFDA approval for Tofacitinib tablets
Aurobindo Pharma rose 1.80% to Rs 1,489.95 after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets in 5 mg and 10 mg strengths.
Stock Alert: CG Power, Juniper Hotels, IL&FS Engineering, Aurobindo Pharma, Karur Vysya Bank
Securities in F&O Ban:
Nifty 50, Sensex May Open Muted Ahead of RBI Policy; Titan, Aurobindo Pharma, Groww in Focus - Dalal Street Investment Journal
Nifty 50, Sensex May Open Muted Ahead of RBI Policy; Titan, Aurobindo Pharma, Groww in FocusDalal Street Investment Journal
Rajesh Exports, Tata Motors PV, Auro Pharma, ICICI Bank and more: Stocks to Watch for June 5
Rajesh Exports defends disclosures after SEBI concerns, Tata Motors targets over 20% PV share by 2030, ICICI Bank gets SEBI warning, Aurobindo wins US FDA nod, CG Power starts new EHV unit. Here are few stocks to track ahead of Friday's trading session.
Aurobindo Pharma receives USFDA approval for Tofacitinib Tablets
The product will be manufactured at APL Healthcare Unit IV, a wholly owned subsidiary of the company and will be launched immediately.
Aurobindo Pharma gets final FDA nod for tofacitinib tablets which target rheumatoid arthritis
The tablets will be manufactured at APL Healthcare unit IV, a wholly-owned subsidiary of the company, and will be launched immediately. Shares of Aurobindo Pharma Ltd ended at ₹1,467, up by ₹26.70, or 1.85%, on the BSE today, June 4.
Stocks in news: Rajesh Exports, Lenskart, Suzlon Energy, Aurobindo Pharma, Tata Motors
Indian markets saw volatility and closed lower on Wednesday. Key companies are in focus due to significant developments. SoftBank reduced its stake in Lenskart. Sebi issued an interim order against Rajesh Exports. Tata Motors revised its Avinya EV strategy. Suzlon Energy is diversifying into battery storage. RIL's subsidiary signed MoUs with the Haryana Government.
Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facility
Aurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines for global markets. US pharma giant MSD is the first major client. The plant signifies Aurobindo's expansion into the growing biologics and contract manufacturing sector. It is set to create over 1,500 jobs.
Stocks to Watch for June 4: Aurobindo Pharma, IndiGo, NBCC and more
From Aurobindo Pharma inaugurating TheraNym, a dedicated biologics contract manufacturing organisation to NBCC securing work orders worth around ₹83.24 crore; here are some stocks to watch on Thursday trading session.
Aurobindo Pharma to attend Trinity India 2026 conference - scanx.trade
Aurobindo Pharma to attend Trinity India 2026 conferencescanx.trade
Stock Market News Today LIVE Updates: Nifty, Sensex Off Day's High In Last-Hour Trade; Aurobindo Pharma, Engineers India Slump Up To 9% - NDTV Profit
Stock Market News Today LIVE Updates: Nifty, Sensex Off Day's High In Last-Hour Trade; Aurobindo Pharma, Engineers India Slump Up To 9%NDTV Profit
Aurobindo Pharma share price plunges 7% as margins weigh on Q4 results
Aurobindo Pharma Q4 results 2026: Aurobindo Pharma has reported a 2 per cent rise in consolidated profit after tax to ₹920.84 crore in the fourth quarter ended March 31.